The investigational antipsychotic lumateperone failed in a phase III study for major depression in patients with bipolar disorder, said developer Intra-Cellular Therapies. The treatment succeeded in a smaller study, however, and is currently being assessed in another as adjunct to lithium or valproate. (Reuters)
Are the DSM’s diagnostic labels for schizophrenia, bipolar disorder, and other psychiatric conditions “scientifically meaningless”? (ScienceDaily)
In related news, people with certain mental health conditions said in a survey that the World Health Organization’s ICD-11 psychiatric diagnostic descriptions should be revised to better encompass the “lived experience” of the disorder and should include more lay language. “We hope that the changes we are recommending would also help clinicians better understand and empathize with the felt experience of service users,” said author Caitlin Notley, PhD, of the University of East Anglia. (Lancet Psychiatry)
Matcha tea powder and extracts helped reduce anxiety by activation of dopaminergic and serotonergic systems in a mouse model. (Journal of Functional Foods)
A genome-wide association study of a Southern Indian population identified a genetic link between schizophrenia and niacin metabolism. (JAMA Psychiatry)
College kids who self-reported “problematic” use of their phones were more likely to abuse alcohol and were at a higher risk for PTSD, anxiety, and depression. (Journal of Behavioral Addictions)
For people with obstructive sleep apnea and cardiovascular disease, a CPAP machine could also help alleviate some symptoms of anxiety and depression. (EClinicalMedicine)
After being granted Breakthrough Therapy Designation and Fast Track Designation by the FDA, NeuroRx announced that they have initiated a phase IIb/III study for their investigational antidepressant NRX-101 for maintaining remission from severe bipolar depression and acute suicidal ideation and behavior following ketamine treatment.
Source: MedicalNewsToday.com
